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Plasma lipoproteins and lecithin:cholesterol acyltransferase distribu-
tion in patients on dialysis. Plasma lipoproteins and LCAT activity were
studied using a single spin density gradient separation and an exogenous
substrate enzyme assay in 41 patients on chronic hemodialysis and in 11
normal subjects. The plasma HDL cholesterol was markedly decreased
(33 vs. 63 mg/dl, P < 0.001) while total and LDL-cholesterol were
unchanged in the patients. Plasma LCAT activity was significantly
lower in the patient group (42 vs. 59 nmoles/4 hr/mi, P < 0.001), but the
distribution of activity (studied in 13 dialysis patients and 12 control
subjects) was not different between the two groups: 90% being associat-
ed with HDL and VHDL lipoprotein fractions. To examine the possible
genetic influence on the development of hypertriglyceridemia in the
patient group, we examined the ratio of apolipoproteins E3/E2 and
Cli/Cill in ten of the patients and another group of 13 control subjects.
The frequency of heterozygotes for E3 deficiency was not different
between the patient (one of ten) and the control (two of 13) groups.
While the patient group had lower Cli/Cill ratio, the figures did not
reach statistical significance. The low LCAT activity in the face of
higher plasma triglycerides and low HDL may contribute to impaired
lipolysis previously documented in uremic patients. A follow-up study
performed 1 year after the initial study confirmed the decreased HDL
(51 vs. 71 mg/dl, P <0.01) and LCAT activity (50 vs. 59 nmoles/hr/ml, P
< 0.02) in an exogenous substrate system (N = 20). LCAT measured
using the endogenous substrate was not significantly different from the
control group (49 vs. 55 nmoles/hr/ml). Changes in LCAT activity
induced by a single dialysis were not significant in either assay system.
Lipoprotéines plasmatiques et distribution de Ia lécithine:cholestérol
acyltransférase chez des malades en dialyse. Les lipoprotéines plasmati-
ques et l'activité LCAT ont été étudiées en utilisant une separation par
centrifugation unique sur gradient de densité et un dosage enzymatique
avec un substrat exogéne chez 41 malades en hemodialyse chronique et
chez ii sujets normaux. Le cholesterol plasmatique HDL Ctait diminuC
de facon marquee (33 contre 63 mgldl, P < 0,001) tandis que les
cholestérols total et LDL Ctaient inchanges chez les malades. L'activitC
LCAT plasmatique était significativement plus faible dans le groupe des
malades (42 contre 59 nmoles/4 hr/ml, P < 0,001), mais Ia distribution
de l'activité (étudiée chez 13 hémodialysés et 12 sujets contrôles) n'Ctait
pas différente entre les deux groupes: 90% etaient associés avec les
fractions HDL et VHDL des lipoproteines. Afin d'examiner une
possible influence genetique sur le developpement d'une hypertrigly-
céridémie dans le groupe des malades, nous avons examine le rapport
des apolipoprotéines E3/E2 et Cu/CuT chez dix des malades et chez un
autre groupe de 13 sujets contrôles. La frequence des heterozygotes
pour un deficit en E3 n'Ctait pas différente entre les groupes des
malades (Un des dit) ou des contrOles (deux des 13). Bien que le groupe
des malades ait eu un rapport Cil/Clil plus faible, les valeurs n'ont pas
atteint La signification statistique. La faibie activité LCAT en presence
de triglycerides plasmatiques plus élevés et de HDL bas pourrait
contribuer a l'anomalie de lipolyse prealablement documentéc chez les
malades uremiques. Une étude évolutive faite un an après l'étude
initiale a confirmé La diminution des HDL (51 contre 71 mg/dL, P < 0,01)
et de l'activité LCAT (50 contre 59 nmoles/hr/ml, P < 0,02) dans un
systéme utilisant un substrat exogène (N = 20). La LCAT mesurée en
utilisant Ic substrat endogène n'était pas significativement diffCrente du
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groupe contrôle (49 contre 55 nmoles/hr/ml). Les modifications d'acti-
vitC LCAT induites par une dialyse unique n'Ctaient pas significatives
dans aucun des systèmes de dosage.
Hyperlipoproteinemia is a well-recognized complication of
renal dialysis. However, despite numerous studies on the
subject (for review see [1, 2]), the etiology of the disorder and
the role played by genetic factors are, as yet, unclear. Since
atherosclerotic vascular disease is more frequent in the dialysis
patients [3, 4] and since one of the risk factors for atherosclero-
sis is hyperlipidemia, it is important to study its pathogenesis.
The accumulation of triglyceride-rich particles [5] results
either from their increased production or decreased catabolism.
In the current study the possibility of low lecithin:cholesterol:
acyltransferase (LCAT) activity and/or unusual LCAT/lipopro-
tein association was investigated. We have attempted to extend
some of the earlier observations by applying newer analytical
techniques to the study of plasma lipoproteins and LCAT
activity in dialyzed patients.
Possible catabolic defects that could result in the observed
lipoprotein patterns include decreased activities of lipoprotein
and/or hepatic lipases, [6, 7], decreased LCAT activity [8—10],
or alterations in fatty acid oxidation [11].
However, since only between 30 and 60% of uremic patients
develop hyperlipidemia [1], we speculated that in addition to
other factors, a genetic predisposition may play a role in its
development. The following questions were addressed:
• Is the LCAT activity reduced in the uremic patient?
Previous studies have shown decreased rates of cholesterol
esterification [8—10]. However, because of the methodologies
employed the influence of patient lipoproteins on the observed
activity has not been accounted for in these studies.
• Is the LCAT/lipoprotein association affected by the uremic
state? The derangement in lipoprotein metabolism may cause a
secondary reduction in the observed LCAT activity. Abnormal-
ly large, triglyceride-rich high density lipoprotein (HDL) parti-
cles may not be suitable for association with the enzyme and
thus increase the enzyme degradation rate.
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Table 1. Patient data
Patient group N Sex Age
Years of
dialysis Medication Diet
Control subjects 12 7M
5F
34 10 None None Western standard
Patients on hemodialysis 41 29M
12F
47 10 4.9 3.8 80% on either phosphate binders, antihyper-
tensives (beta blockers), or sedatives Higher in carbohydratesand fat, low protein
a Values are mean SD.
• Is there an abnormality of apolipoprotein of the triglycer-
ide-rich particles which reduces their catabolism, that is, have
the uremic patients who develop hyperlipidemia inherited an
apolipoprotein makeup which may influence the catabolism of
their triglyceride-rich particles? One such possibility is apo E-3
deficiency [12], the frequency of which has not been investigat-
ed in uremic patients.
• Does the dialysis procedure itself affect the LCAT activity
observed in a chronically dialyzed uremic patient? A recent
study [13] suggests that dialysis may normalize both cholesterol
transfer and lysolecithinase activities of LCAT.
Methods
Study design. The study involved two phases: Phase 1.
Plasma lipids, lipoproteins and LCAT activity were measured
in a heterogeneous group of 41 patients undergoing hemodialy-
sis in a local renal unit. In addition, analysis of very low density
lipoprotein (VLDL) apolipoproteins C and E by isoelectric
focusing was performed on ten patients where elevations of
plasma lipids were observed. Density gradient ultracentrifuga-
tion of 13 plasma specimens, representative of the total study
group, was utilized to investigate the LCAT/lipoprotein
association.
Phase 2. Twenty hemodialysis patients (14 of whom were
also investigated in Phase 1) were sampled for analysis of
plasma lipids, lipoproteins and LCAT activity. Specimens were
obtained before and after a single dialysis procedure. LCAT
activity was determined by endogenous and exogenous sub-
strate procedures for comparison. This phase of study was
undertaken approximately 1 year after the first.
Phase 1
Control subjects. Normal control subjects for LCAT and lipid
studies were 12 apparently healthy laboratory employees and
students, five men and seven women, age 34 10 years (mean
SD). Control subjects for the study of apolipoprotein compo-
sition of VLDL were seven men, six women, aged 36 9 years
whose plasma was analyzed for "quality control" purposes
during the investigation of Shaughnessy Hospital Lipid Clinic
patient population in Vancouver, British Columbia, Canada.
Hemodialysis subjects. Table 1 describes the overall patient
population used for this phase. We studied the entire control
and patient population with regard to plasma lipids and LCAT
activity. However, patients for the other analyses were chosen
on the basis of their plasma lipid values. The range of plasma
cholesterol and triglyceride of these subgroups is indicated with
the appropriate results. For the analysis of apo E and C
isomorphs, the patients chosen had plasma triglycerides greater
than 150 mg/dl with moderate elevations in plasma cholesterol.
Specimens. EDTA plasma was obtained after an overnight
fast whenever possible. However in a number of hemodialysis
patients, the specimens were obtained at various times post-
prandially. All specimens were collected immediately prior to
the onset of the dialysis procedure. Whole blood specimens
were stored at 4°C for various intervals up to 24 hr after
venipuncture before processing. Control experiments showed
less than a 5% difference in either LCAT activity or lipid values
between specimens stored frozen at —20°C immediately and up
to 48 hr of storage at 4°C. All control specimens were handled in
the identical manner to those of the patients.
Analytical techniques. LCAT assays were performed using
heat-inactivated HDL as substrate. Substrate lipoproteins were
isolated by sequential ultracentrifugation. High density parti-
cles were isolated between densities 1.063 and 1.21 g/ml and
were washed once at the lower density limit in a fourfold excess
of density solution. Residual LCAT was inactivated by heating
to 58°C for 30 mm. The working substrate was prepared by
mixing HDL, 7-3H-cholesterol in 5% bovine serum albumin
emulsion 12, 5% BSA, and 0.2 M sodium phosphate pH 6.9 in
the ratio 1:2:5:8. After equilibration of labelled cholesterol at
37°C in a shaking water bath for 4 hr, the preparation was again
heated to 58°C for 30 mm. Precipitating protein was removed by
low-speed centrifugation and the preparation was stored at 4°C
for a maximum of 3 weeks. Incubations were initiated by the
addition of 0.20 ml of prewarmed substrate to 20 tl of LCAT-
containing sample and were terminated, after 4 hr in a shaking
37°C bath, as described elsewhere [14]. Radioactivity in the
lipid extract was separated into free and esterified cholesterol
by TLC on silica gel G (Polygram, Machery-Nagel, Brinkman
Instruments, Inc., Westbury, New York) in petroleum ether:
diethyl ether: acetic acid (70:10:1). Free and ester spots were
cut from the plate and counted in Omniflour (New England
Nuclear Corporation, Boston, Massachusetts) scintillation
cocktail. Aliquots of quick-frozen serum pools (—70°C) were
analyzed in each batch of patient samples. The inter-run
coefficient of variation using this assay method was 17% at the
transferase level of 34 nmoles FC/4 hr/ml.
This substrate gives lower levels for LCAT activity than
published elsewhere, presumably due to the lack of cholesteryl
ester acceptor in the system. A standardized substrate for
LCAT was not available at the time of the first phase. Our
experience has been that due to the variability in the exogenous
substrates, a control group must be included with each batch of
substrate used. The rate of esterification is approximately four
times lower with our HDL substrate than with the Stokke-
Norum assay; thus, when expressed as esterification per 4 hr,
the numerical values are similar.
Plasma VLDL for apo E and apo C isomorphs were isolated
as described in the Lipid Research Clinic procedures manual
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Table 2. Plasma LCAT activity and lipid values in patients on renal hemodialysis
LCAT
nmoleslml/4 hr
Cholesterol, mg/dl
Triglycerides
mgldlTotal Free LDL HDL
Normal control
(N = 11)
59.0 178.6 41.1
10.0
99.6 63.4 78.6
Dialysis(N = 41)
42.0 184.5 42.2 104.0 32.8 221.6"
Statistical significanceb P < 0.001 NS NS NS P < 0.001 (P < 0.001)"
The mean SD LCAT was measured using a pooi of heat-inactivated human HDL as a substrate; 33.7 nmoles FC per assay.
b Values were obtained with use of the Student's I test.
"Most of the patient specimens were taken during non-fasting periods (see Results).
[15] at density 1.006 gIml and washed once at the same density.
Chylomicrons were not separated from the VLDL fraction.
Delipidation of the purified VLDL and isoelectric focusing were
performed as described by Warnick et al [16]. Isomorphs were
identified and ratios calculated after densitometric scanning
(Helena Quickscan). Cholesterol, triglycerides and HDL cho-
lesterol were determined by previously described techniques
[17] using enzymatic reagents. LDL cholesterol was calculated
by the method of Fredrickson [181.
Distribution of LCAT among lipoprotein density fractions
was determined by a modification of the method of Chung et al
[19]. Briefly, plasma densities were increased to 1.30 gIml by
the addition of solid sodium bromide; 4.0 ml of density adjusted
plasma were overlayed with 9.5 ml of d = 1.006 g/ml saline and
subjected to ultracentrifugation for 5.1 x l0 glmin (70,000 rpm
for 2.5 hr in 75 Ti rotor). At the conclusion of the centrifugation,
the tubes were fractionated into approximately 20 equal frac-
tions by tube puncture. Cholesterol was measured in each
fraction to describe the lipoprotein profile. The density profile
for this method was determined using d = 1.30 gIml sodium
bromide solution in place of plasma. Fractions were pooled
according to their cholesterol/trigylceride content and their
position in the density gradient to represent five lipoprotein
fractions: very low density (VLDL), intermediate density
(IDL), low density (LDL), high density (HDL), and very high
density lipoprotein (VHDL). Each lipoprotein fraction was
dialyzed for 20 hr in 100-fold excess of 5 mt'vi EDTA pH 7.4 and
its final volume and LCAT activity were determined. Recovery
of LCAT from the starting plasma ranged from 74 to 120% with
a mean value of 102% (N = 14).
Phase 2
Control subjects. The control group for all analyses in this
phase consisted of 17 laboratory employees, seven men and ten
women, aged 42 14 years (mean SD).
Hemodialysis subjects. The study group represents a sample
of 20 patients from a chronic dialysis ward at Vancouver
General Hospital. Fourteen of these individuals had been
studied previously. The age distribution of the group was 48
13 years. Twelve of the patients were male, eight were female.
Specimens. EDTA blood samples were obtained immediately
prior to and immediately following the hemodialysis procedure.
Whole blood was stored on ice until processing. Within 4 hr of
venipuncture, plasma was separated from cells by centrifuga-
tion and stored at —20°C. Control samples were handled in the
identical manner. No attempt was made to control diet in either
group and all predialysis specimens were obtained 2 to 4 hr
postprandially.
Analytical techniques. LCAT enzyme assays were performed
by two methods, designated exogenous substrate and endoge-
nous substrate. The exogenous substrate assay was performed
as described by Chen and Albers [201 with one modification.
The proteoliposomes contained less phosphatidylcholine (Sig-
ma type III-E) to give a molar ratio of lecithin to cholesterol of 4
to 1 as used by Matz and Jones [21]. The endogenous substrate
assay was that of Stokke and Norum [22] as modified by Lacko,
Rutenberg, and Soloff [14]. The between run coefficients of
variation for these methods are 10 and 12%, respectively, in our
laboratory.
Plasma lipid and lipoprotein analyses were performed as
described above.
Results
Phase 1. The results of plasma lipids and LCAT assays are
shown in Table 2. Similar to previous reports [9, 23] this group
of uremic patients showed a decrease in plasma HDL cholester-
ol while the values for both total and LDL cholesterol were not
different from the control group. The triglyceride values are
higher in the patient group but since only a minority of blood
specimens (11 out of 41) were obtained in a fasting state, the
absolute values are not representative of true differences be-
tween the control and patient groups. However, it is of interest
that despite the higher plasma triglycerides, the LCAT activity
measured by an exogenous substrate method is markedly lower
in the patient group. Previous studies have shown that both in
the normolipidemic [24] and the hypertriglyceridemic popula-
tions [25] postprandial lipemia is associated with an increase in
LCAT activity.
The distribution of LCAT activity and plasma lipoprotein
fractions was studied by a single spin ultracentrifugation of
plasma from 12 control subjects and 13 hemodialysis patients
(Table 3 and Figs. 1 and 2). Decreases in HDL, increases in
VLDL and similarities of LDL cholesterol can be readily seen.
In addition, broadening of HDL and LDL with a tendency
toward lower density is depicted. This observation is consistent
with triglyceride enrichment of all lipoprotein classes previous-
ly described [5]. No differences in the distribution of LCAT
among the lipoprotein fractions were detected between control
and dialysis groups.
Data on isoforms of apolipoproteins E and C in the d < 1.006
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Table 3. LCAT distribution in single spin density gradient
Patient group N
LCAT distribution (%) ma
.
Triglycerides
mgldl
Cholesterol
mgldlVHDL HDL LDL IDL VLDL
Control subjects
Dialysis
12
13
34.5
33.6
17.6
15.4
56.5 20.7
56.6 20.9
3.6 3.2
5.4 4.1
4.3 4.2
2.2 2.5
1.1 1.0
2.9 3.5
85 29
180 53
173 30
195 43
Abbreviations: N, number of patients; VHDL, very high density lipoprotein; HDL, high density lipoprotein; LDL, low density lipoprotein; IDL,
intermediate density lipoproteins; VLDL, very low density lipoproteins.
a The percentage represents recovered LCAT activity (mean SD).
Fig. 1. Lipid distribution profile in single spin density gradient ultracen-
trifugation—normal profile.
fraction in normal and uremic patients are summarized in Table
4. There was no difference in the E31E2 ratio between the two
groups, and the number of heterozygotes for E3 deficiency
(defined as E3/E2 < 1.2) was one of ten and two of 13, in the
patient and control groups, respectively. A tendency (albeit
statistically insignificant at P = 0.05) for a decreased Cli/Cill
ratio observed in the uremic patients was noted. Such a ratio
may be unfavorable for an optimal activation of lipoprotein
lipase [26].
Phase 2. The plasma lipid, lipoprotein, and LCAT data for
the control and predialysis samples are shown in Table 5. In
agreement with our previous findings HDL, triglycerides, and
LCAT activity in the exogenous substrate system were signifi-
cantly different in the patient group. However, the differences
were not nearly as striking as those observed earlier. In
addition, no significant difference was observed in LCAT
activity by the endogenous substrate method.
To verify that uremic plasma does not contain a dialysable
inhibitor of LCAT, activity was measured by both methods
after the dialysis. Results are shown in Table 6. No significant
changes were detected in either assay. However, LCAT activi-
ty measured by the endogenous substrate technique did in-
crease slightly. Plasma lipids and lipoproteins were unaffected
with the possible exception of triglycerides which appeared to
decrease in most cases.
2 4 6 8 10 12 14 16 18 20
Fraction number
Fig. 2. Lipid distribution profile in single spin density gradient ultracen-
trifugation—hemodialysis profile.
Discussion
Our results show abnormalities of the lipoprotein density
class distribution as well as a decrease in LCAT activity in the
plasma of uremic patients when an exogenous substrate assay is
used. It is likely that this finding reflects an actual decrease in
the enzyme mass [27, 28] and less likely the presence of enzyme
inhibitors in patient plasma, since the dialysis procedure had no
effect on observed activity. The distribution among the plasma
lipoprotein fractions of LCAT activity was identical in the
control and patient groups. Our findings in the control group are
similar to those of Chen and Albers [291 who used a single spin
density gradient to study LCAT activity and mass distribution
in normal subjects.
Although decreases in HDL and LCAT were significant in
both phases of the study, the magnitude of the changes was
different. This discrepancy is not likely due to differences in the
control groups since there were no differences in plasma LCAT
activity between Phases 1 and 2 controls measured by the
proteoliposome assay. A number of patients participating in
Phase 1 who had extremely low levels of LCAT and HDL were
unavailable for Phase 2. Three had died, two were recently
transplanted, two were changed to peritoneal dialysis, and one
had a cerebro-vascular accident. A longitudinal study (using a
standardized and reproducible LCAT assay) will be required to
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Table 4. Apo-VLDL distributiona
Group N
Plasma triglycerides
E3/E2 CIL/Cill E4 frequency mg/dl
Plasma cholesterol
mg/dl
Control subjects
Dialysis
13
10
2.00 0.78 0.39 0.24 4/13 117 63
1.69 0.55 0.27 0.02 1/10 388 135
200 30
250 55
Values are mean SD.
Table 5. Plasma LCAT and lipids in hemodialysis patients—Phase 2
Groups Age
LCAT activity
nmoles/hr/ml Cholesterol, mg/dl
.
Triglycerides
Endogenous Exogenous Total Free LDL HDL mg/dl
Control(N 17) 42 55.1 59.3 196 53 10612.6 10.7 71 91
Hemodialysis(N = 20)
48 49.0 49.8 209 58 118 51 250
Level of significancea NS NS P < 0.02 NS NS NS P < 0.01 P < 0.001
See Table 3 for abbreviations.
a Values were determined by Student's (test.
Table 6. Effect of dialysis on plasma lipids and LCAT activity
LCAT, nmoles/hr/ml Cholesterol, mg/dl
Total Free HDL
Triglyc-
enides
mg/dlEndogenous Exogenous
Pre- 49.0 49.8 209 58 51 250
dialysis
Post- 55.0 48.6 223 61 54 238
dialysis
determine the possible prognostic significance of plasma LCAT
activity in chronic uremia.
Our results differ from those of Bones, Subbaiah, and Bag-
dade [131 in terms of changes induced in LCAT activity by the
dialysis procedure. The differences may be related to either the
method of LCAT assay or to the choice of patients. Bones,
Subbaiah, and Bagdade used a different exogenous substrate
(pooled heat-inactivated plasma). They did not specify the
duration of dialysis in their patients except by the statement
that it was over 3 months while our patients have been on
dialysis on the average for 5 years. LCAT activity may not be
improved by dialysis over the longer term. The determination of
LCAT mass in chronic and acute uremia may clarify the
situation.
It is of interest that in contrast to our findings in dialysis
patients, LCAT activity and secretion in both normal and
hypertriglyceridemic individuals is positively correlated with
the concentration of plasma triglycerides [24, 25]. Moreover, a
direct relationship between LCAT activity and triglyceride
secretion into the incubation media of cultured rat hepatocytes
was reported by Nordby et al [30]. It is therefore tempting to
speculate that in the uremic patients either there is a dissocia-
tion between the secretion of triglyceride rich particles and
LCAT activity or, due to a limited opportunity for complex
formation with apo A-I and D [31], faster inactivation (or
catabolism) of LCAT takes place.
The finding of a normal, approximately 20% [12], frequency
of heterozygosity for E3 deficiency in both groups suggests that
this genetic trait is not related to either the kidney failure itself
or the accompanying hypertriglyceridemia. Whether such a
pattern is also seen in uremic patients with gross hypertniglycer-
idemia remains to be determined. Recent observations by
Nestel, Fidge, and Tan [5] suggest that at least part of the
abnormalities can be explained by accumulation of lipoprotein
remnants which are rich in triglyceride and have increased
amounts of apo E and apo A-IV. The decreased ratio of apo CII
to apo CIII in VLDL is consistent with the observations of
Holdsworth et al [32] and Staprans, Felts, and Zacherle [26] and
suggests the possibility of abnormalities of these apoliproteins
in renal disease. It is possible that alterations of A! and All in
HDL may affect LCAT activity in uremia. Clearly, more
investigation in this direction is required.
Other factors, for example, relatively high carbohydrate diet,
possibly the medications (the effect of beta blockers on plasma
lipoproteins is now somewhat controversial), and decreased
physical activity, may contribute to the hypertniglycenidemia of
patients on dialysis. The decreased LCAT activity and the
possible abnormality in Cli/CIII ratio are not likely the major
causes of, but they may contribute to, the observed lipoprotein
abnormalities.
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